A second straight record close for the valve maker at $107.19, 1.3% above Thursday's peak. Medtronic rose 1.88% and Abbott 1.22% the same day, so the medtech bid was broad.
Moves: Nov 13, 2026 · Alpha Vantage daily close
Headquartered in Abbott Park, IL Fiscal year ends December NYSE: ABT abbott.com
Abbott Laboratories is a global healthcare company with a diversified portfolio spanning four major segments: Medical Devices (including electrophysiology, rhythm management, heart failure, vascular, structural heart, neuromodulation, and diabetes care with its FreeStyle Libre continuous glucose monitoring platform), Diagnostics (core laboratory diagnostics, rapid and molecular diagnostics, and cancer diagnostics following the 2026 acquisition of Exact Sciences and its Cologuard colorectal cancer screening platform), Nutrition (pediatric and adult nutritional products sold globally), and Established Pharmaceuticals (branded generic medicines sold primarily in key emerging markets across Latin America, Asia Pacific, and other international regions). The company employs approximately 122,000 people and serves customers in more than 160 countries. Abbott's medical devices business accounts for the largest share of revenue, with continuous glucose monitors and electrophysiology products among its fastest-growing product lines. Updated
A second straight record close for the valve maker at $107.19, 1.3% above Thursday's peak. Medtronic rose 1.88% and Abbott 1.22% the same day, so the medtech bid was broad.
Moves: Nov 13, 2026 · Alpha Vantage daily close
A former Pentagon undersecretary just disclosed 57 trades in one filing, with the heaviest buying in semiconductors and electronics manufacturing: NXP, ON Semiconductor and Benchmark Electronics all picked up in size. The disclosure landed 39 days after the earliest trade.
Retirees who want income that keeps coming through recessions, rate swings and market scares often start with health care. People need heart devices, diagnostic tests and cancer drugs in every economy, and…
Hospitals reorder syringes, sensors, and implants whether the economy booms or stalls, and three device makers turn that habit into payouts that grow every year. Only one has a streak long enough…
Arthritis flares, cholesterol checks and cancer treatments arrive on their own schedule, in recessions and booms alike, which is why healthcare draws attention from retirees building an income plan. It also gives…
AbbVie built its empire on a single blockbuster drug, then watched biosimilars gut it almost overnight. Whether the replacement pipeline saved investors or left them holding the bag depends on when they…
Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance sheet strength could…
Medtronic just extended a nearly half-century dividend streak, but its raise barely outpaces inflation while rivals like Abbott and J&J grow payouts far faster. Whether explosive growth in cardiac ablation can close…
AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee…
Six Dividend Aristocrats shoulder a big chunk of SCHD's 3.8% yield, but two of them are paying dividends that their earnings barely cover. Here is how close to the edge each one…
Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics. Three healthcare stocks prove that the most reliable paycheck…
Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than…
Pre-Market Stock Futures: Futures are trading lower as today’s oil and interest rates are higher. Baseball legend Babe Ruth was often credited with the saying, “Records are made to be broken,” and…
Both Medtronic and Abbott have dropped in 2026, and those declines reshuffled the math on yield, valuation, and long-term growth in ways that push retirement investors toward a clear but maybe surprising…
Altria (NYSE:MO | MO Price Prediction) sends its latest quarterly check of $1.11 per share to shareholders on October 9, 2026. The prior rate was $1.06, so the raise works out to…
AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.
Medtronic has raised its dividend for 49 straight years while the stock quietly lost a fifth of its value, but something in the operating room just changed the entire conversation about why…
Abbott Laboratories is a global healthcare company with a diversified portfolio spanning four major segments: Medical Devices (including electrophysiology, rhythm management, heart failure, vascular, structural heart, neuromodulation, and diabetes care with its FreeStyle Libre continuous glucose monitoring platform)…
24/7 Wall St.'s 12-month price target for ABT is $119.02, rated Buy. The Wall Street consensus target is $118.91. ABT price prediction →